NEW YORK, Feb 21 – Lynx Therapeutics reported a 37 percent drop in fourth-quarter 2000 revenues to $3.3 million, compared with $10.1 million in the year ago quarter, as revenues from technology access and service fees as well as collaborative research fell.

In the fourth quarter, Lynx posted revenues from technology access and service fees of $3.2 million, compared with $5.1 million in fourth-quarter 1999. Revenues from collaborative research plummeted to $125,000, from $5.0 million in the year ago period.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.